| # | Title | Journal | Year | Citations |
|---|
| 1 | The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer | Critical Reviews in Oncology/Hematology | 2013 | 1,106 |
| 2 | A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer | British Journal of Cancer | 2012 | 391 |
| 3 | Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial | Lancet Oncology, The | 2015 | 325 |
| 4 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial | Lancet Oncology, The | 2020 | 304 |
| 5 | Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review | Oncologist | 2012 | 265 |
| 6 | Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial | Supportive Care in Cancer | 2012 | 179 |
| 7 | Bisphosphonates and other bone agents for breast cancer | The Cochrane Library | 2018 | 155 |
| 8 | Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression | Clinical Genitourinary Cancer | 2019 | 131 |
| 9 | Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients | Journal of Vascular and Interventional Radiology | 2012 | 122 |
| 10 | Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing | Journal of Vascular and Interventional Radiology | 2020 | 113 |
| 11 | Lay constructions of decision-making in cancer | Psycho-Oncology | 2002 | 105 |
| 12 | Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study | British Journal of Dermatology | 2020 | 104 |
| 13 | Bisphosphonates and other bone agents for breast cancer | British Journal of Dermatology | 2012 | 98 |
| 14 | IQGAP1 and IGFBP2 | Journal of Neuropathology and Experimental Neurology | 2007 | 84 |
| 15 | Antiangiogenic therapy for high-grade glioma | The Cochrane Library | 2014 | 84 |
| 16 | Anti-angiogenic therapy for high-grade glioma | The Cochrane Library | 2018 | 81 |
| 17 | Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma | Journal of Thoracic Oncology | 2018 | 75 |
| 18 | Use of Inflammatory Markers to Guide Cancer Treatment | Clinical Pharmacology and Therapeutics | 2011 | 73 |
| 19 | Responding to the active and passive patient: flexibility is the key | Health Expectations | 2002 | 72 |
| 20 | Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics | Clinical Pharmacokinetics | 2012 | 72 |
| 21 | Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors | JAMA Oncology | 2018 | 68 |
| 22 | The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition | Cancer | 2014 | 65 |
| 23 | Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma | Expert Opinion on Biological Therapy | 2006 | 60 |
| 24 | Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer | The Cochrane Library | 2017 | 60 |
| 25 | Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey | Supportive Care in Cancer | 2017 | 59 |
| 26 | Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients | BMC Cancer | 2016 | 57 |
| 27 | Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic | JCO Oncology Practice | 2020 | 56 |
| 28 | Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target | Histopathology | 2017 | 52 |
| 29 | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice | Journal of Clinical Medicine | 2014 | 51 |
| 30 | Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis | Journal of Clinical Medicine | 2021 | 46 |
| 31 | Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis | EJNMMI Research | 2017 | 45 |
| 32 | Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17 | Annals of Oncology | 2013 | 44 |
| 33 | A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study | Neuro-Oncology | 2021 | 44 |
| 34 | Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care | Annals of Oncology | 2011 | 41 |
| 35 | Health-related quality of life and inflammatory markers in malignant pleural mesothelioma | Supportive Care in Cancer | 2013 | 38 |
| 36 | Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? | Journal of Clinical Neuroscience | 2009 | 37 |
| 37 | Expanding the spectrum of IDH1 mutations in gliomas | Modern Pathology | 2013 | 37 |
| 38 | Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy | Pigment Cell and Melanoma Research | 2018 | 34 |
| 39 | Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy | BMC Cancer | 2019 | 34 |
| 40 | Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) | Scientific Reports | 2019 | 34 |
| 41 | Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. | Journal of Clinical Oncology | 2020 | 34 |
| 42 | Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM) | PLoS ONE | 2013 | 33 |
| 43 | The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis | Journal of Neuro-Oncology | 2019 | 31 |
| 44 | Ethical communication in clinical trials | Cancer | 2002 | 30 |
| 45 | Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres | Journal of Vascular and Interventional Radiology | 2010 | 30 |
| 46 | Optimal management of bone metastases in breast cancer patients | Breast Cancer: Targets and Therapy | 2011 | 30 |
| 47 | The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine | Lung Cancer | 2012 | 30 |
| 48 | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma | Neoplasia | 2016 | 30 |
| 49 | Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade | Supportive Care in Cancer | 2019 | 30 |
| 50 | Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis | Journal of Neuro-Oncology | 2019 | 30 |
